GSK (GSK) and Japan's Shionogi said Wednesday that the latter has completed its acquisition of 11.7% stake in ViiV Healthcare from Pfizer (PFE) for about $2.13 billion.
Under the terms, Pfizer received $1.88 billion while GSK received a special dividend of $250 million, payable in British pounds, the companies said.
With the acquisition, Shionogi now owns a 21.7% economic stake in ViiV, while GSK retains its 78.3% majority stake, according to the parties.
The deal was first announced on Jan. 20.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments